New Data: Leqembi’s Expanding Benefit for Early Alzheimer’s
Modeled long-term analyses from the Clarity AD open-label extension estimated that continuous lecanemab could delay progression from mild cognitive...
New Hope for APL: Quetzal Starts Phase III QTX-2101 Trial
Quetzal Therapeutics has opened a global, randomized Phase III trial of QTX-2101, an oral arsenic trioxide capsule, in newly...
Kymera to Announce KT-621 Atopic Dermatitis Trial Results
In a Phase 1 study in healthy volunteers, Kymera’s oral STAT6 degrader KT-621 achieved complete STAT6 degradation in blood...
New Hope in NSCLC: Enozertinib’s Powerful CNS Activity
Topline data from ORIC’s Phase 1b study of enozertinib (ORIC-114) in EGFR exon 20–mutated NSCLC show a 67% best...
Parkinson’s Trial: Solengepras Shows Remarkable Results
Solengepras reduced average daily OFF time by 1.3 hours versus placebo after 27 days (p=0.02) in a randomized Phase...
Apeiron Presents First-in-Human Data for GTA182 in NSCLC
Topline readout: In an ongoing Phase 1 study of GTA182 in MTAP-deleted solid tumors, the objective response rate was...
Bioversys Launches Promising Phase 3 Trial for BV100 Drug
In a Phase 2 study in ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii, BV100 delivered a 50% relative...
Study Assesses Emrosi™ (DFD-29) Impact on Microbial Flora
In a 60-subject, randomized, double-blind, placebo-controlled Phase 1 study, 16 weeks of low-dose oral minocycline (Emrosi, 40 mg modified-release;...
Atumelnant Pivotal Trial for Adult CAH Doses First Patient
Phase 2 data for atumelnant in adults with classic congenital adrenal hyperplasia (CAH) showed rapid, substantial and sustained reductions...
Rapid Resolution Lifts Hold on Tenaya’s Gene Therapy Trial
FDA has lifted the clinical hold on Tenaya’s MyPEAK-1 Phase 1b/2a trial of TN-201 in MYBPC3-associated hypertrophic cardiomyopathy, with...